Target intelligence / Profile preview

PKMYT1 associated long non-coding RNA (PKMYT1AR)

Target
PKMYT1AR
Molecular classification
Long non-coding RNA (lncRNA), Other (regulatory non-coding RNA)
01

Overview

PKMYT1 associated long non-coding RNA (PKMYT1AR) is a human-specific lncRNA (also known as ENST00000595422) that is overexpressed in non-small cell lung cancer (NSCLC) and is associated with poor clinical outcomes. It is transcriptionally activated by the Yin Yang 1 (YY1) transcription factor and predominantly localized in the cytoplasm. PKMYT1AR acts as a ceRNA by sponging miR-485-5p, leading to upregulation of the protein kinase PKMYT1, which in turn enhances Wnt/β-catenin signaling and cancer stem cell maintenance by inhibiting the ubiquitin-mediated degradation of β-catenin. Knockdown or inhibition of PKMYT1AR impairs tumor cell proliferation, migration, xenograft tumor formation, and cancer stem cell phenotypes in cell and animal NSCLC models. This molecule is not a protein but a regulatory lncRNA, tightly coupled to cancer biology as a potential diagnostic, prognostic, and therapeutic target in lung cancer and potentially in other cancers where the PKMYT1/β-catenin/Wnt axis is relevant.

Other names
ENST00000595422
02

Mechanism of action

Acts as a competitive endogenous RNA (ceRNA) for miR-485-5p, upregulating PKMYT1 expression by sequestering miR-485-5p and thereby relieving its repression on PKMYT1. Promotes Wnt/β-catenin pathway signaling by stabilizing β-catenin through downstream effects on PKMYT1.

03

Biological functions

Regulation of cell proliferationRegulation of cell migrationMaintenance of cancer stem cells (CSCs)Modulation of Wnt/β-catenin signaling pathwayInhibition of β-TrCP1-mediated ubiquitin degradation of β-catenin
04

Disease associations

CancerCancer stem cell maintenanceTumor metastasisDrug resistance in cancer (notably NSCLC)
05

Safety considerations

As ASOs targeting PKMYT1AR are investigational, general ASO-related risks (e.g., off-target effects, immunogenicity) may apply, but target-specific clinical safety data are not yet described
06

Interacting drugs

antisense oligonucleotides (ASOs)
07

Biomarkers

High PKMYT1AR expression in tumor tissues and blood correlates with poor prognosis in NSCLCPKMYT1AR (itself) can be assayed as an RNA biomarker in tissue and serumAssociated markers: PKMYT1miR-485-5pβ-cateninCD133 (CSC biomarker)

Beyond the preview

Go deeper on PKMYT1 associated long non-coding RNA (PKMYT1AR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PKMYT1 associated long non-coding RNA (PKMYT1AR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call